Objectives
The use of big data to assess the effectiveness of oncological treatments in clinical practice is gaining increasing interest. This analysis aimed to assess the overall survival of metastatic non-small cell lung (met-NSCLC) patients receiving chemotherapy (CT) or immunotherapy (I/O) as 1st line by using real-world data in a sample population in Italy.
Methods
A retrospective observational analysis based on administrative data from a sample of Italian Local Health Units was conducted. Met-NSCLC patients starting a 1st line therapy with CT or I/O between 2017-2018 were identified. Stopping inclusion period up to 2018 enabled at least a two-years follow-up period for each included patient. Kaplan Meier overall survival analysis considered time (months) from therapy initiation to death. Multivariable analysis was performed to adjust for cofounders such as age, gender, metastasis, BRAF test prescription and pharmacological treatments.
Results
A total of 3,126 (mean age±SD 68.6±9.8 years, 68.2% male) and 316 (mean age±SD 68.6±9.7 years, 74.4% male) patients initiated treatment with CT and I/O respectively. In both groups, the more frequent metastases detected were related to lymph nodes (42.1% CT, 24.1% I/O), bone (25.8% CT, 14.9% I/O) and brain (18.3% CT, 10.1% I/O). Median [95%CI] survival was 8.0 [7.4-8.6] and 14.6 [12.2-18.9] months for CT and I/O patients, respectively. Death was not reported in 31.2% of CT and in 44.3% of I/O cohorts. Multivariable analysis showed the risk of death to be significantly lower in patients treated with I/O compared to CT (HR [95%CI] 0.796 [0.681-0.930]).
Conclusions
Results from our study showed among met-NSCL patients in 1stline a better overall survival of the I/O compared to CT patients and a reduced risk of death of I/O vs CT-treated patients. Our findings suggest real-world data could produce valuable insights into treatments and their outcomes in routine daily oncology practice, thus integrating the evidence from clinical trials.
Article info
Identification
Copyright
© 2021 Published by Elsevier Inc.
User license
Elsevier user license | How you can reuse 
Elsevier's open access license policy
Elsevier user license
Permitted
For non-commercial purposes:
- Read, print & download
- Text & data mine
- Translate the article
Not Permitted
- Reuse portions or extracts from the article in other works
- Redistribute or republish the final article
- Sell or re-use for commercial purposes
Elsevier's open access license policy
